Alibaba Health Information Technology Limited
ALBBY
Other OTC9.48
USD
- -
- -
ISIN
US01609Y1082
CUSIP
01609Y108
Return %
Stock
S&P500
1Y
-14.52
26.53
3Y
-24.82
76.60
5Y
-80.85
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Difan Shen
- Full Time Employees
- 1,422
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- Tower One Causeway Bay Hong Kong
- IPO Date
- Sep 30, 2019
- Website
- alihealth.cn
- Similar Companies
- Business
- Alibaba Health Information Technology Limited is an investment holding company primarily engaged in providing Internet technology solutions, service tools, and platforms for the medical and healthcare sectors. The company operates a comprehensive pharmaceutical e-commerce platform; pharmaceutical direct sales; consumer healthcare product sales; digital healthcare services including drug safety tracking and anti-counterfeiting solutions through its "Ma Shang Fang Xin" platform; as well as cloud computing and big data-enabled internet healthcare services. Alibaba Health acts as the healthcare flagship platform of Alibaba Group, focused on integrated online and offline medical and healthcare resource solutions within China. Founded in 1998 and headquartered in Hong Kong, the company serves a broad customer base including pharmaceutical companies, healthcare institutions, and consumers across China. Recent major developments include a strategic acquisition deal announced in late 2023, under which Alibaba Health acquired rights related to Alibaba’s digital marketing platform Alimama to enhance its advertising and promotional content validation capabilities for healthcare products, expected to drive revenue growth and improve service delivery to online retailers. In 2024, Alibaba Health reported robust growth with total revenue increasing to RMB 14.27 billion and net profit rising by 72.8% year-on-year, driven primarily by significant expansion in pharmaceutical e-commerce and direct sales businesses supported by a broader product offering and enhanced advertising capabilities. The company also continues to invest in its digital infrastructure and AI applications across business segments to optimize operational efficiency and expand its healthcare service offerings with an ambition to serve 500 million people within five years. Alibaba Health’s recent operational adjustments include business streamlining efforts in its healthcare and digital services sector to focus on high-growth and high-margin areas. The company’s business segments encompass internet healthcare technology solutions, pharmaceutical supply chain services, consumer healthcare e-commerce platforms, and innovative digital health management. Alibaba Health’s platform ecosystem integrates pharmaceutical product sales, medication safety tracking, and healthcare content services to meet the evolving needs of China’s healthcare market. Alibaba Health Information Technology Limited is a subsidiary of Alibaba Group, headquartered in Causeway Bay, Hong Kong. It was founded in 1998 and formally adopted its current name in 2014 following a reorganization from CITIC 21CN Company Limited. The company employs over 1,300 people and maintains a strategic focus on leveraging digital technologies, including AI and big data, to transform healthcare services in mainland China. Recent acquisitions and partnerships signify Alibaba Health’s intent to consolidate its market leadership in pharmaceutical e-commerce and digital healthcare innovation.